| 69.54 0.3 (0.43%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 84.66 | 1-year : | 98.88 |
| Resists | First : | 72.48 | Second : | 84.66 |
| Pivot price | 68.54  |
|||
| Supports | First : | 67.97 | Second : | 65.19 |
| MAs | MA(5) : | 69.94 |
MA(20) : | 68.09 |
| MA(100) : | 67.45  |
MA(250) : | 75.33 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 58.9 |
D(3) : | 63.8 |
| RSI | RSI(14): 57.7 |
|||
| 52-week | High : | 93.25 | Low : | 54.11 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DXCM ] has closed below upper band by 32.7%. Bollinger Bands are 41% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 70.41 - 70.83 | 70.83 - 71.24 |
| Low: | 68.01 - 68.51 | 68.51 - 68.99 |
| Close: | 68.78 - 69.51 | 69.51 - 70.21 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Mon, 19 Jan 2026
Dexcom (DXCM) releases preliminary, unaudited results for Q4 2025 - MSN
Mon, 19 Jan 2026
Is Dexcom the Next Sleeper Stock? The Real Talk on This Glucose Tech Giant - AD HOC NEWS
Sat, 17 Jan 2026
Is DexCom Stock Underperforming the S&P 500? - MSN
Fri, 16 Jan 2026
DexCom Stock Declines Following Strong Preliminary Q4 Results - TradingView — Track All Markets
Fri, 16 Jan 2026
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - Finviz
Thu, 15 Jan 2026
How Do Investors Really Feel About DexCom Inc? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 390 (M) |
| Shares Float | 387 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 99.6 (%) |
| Shares Short | 13,120 (K) |
| Shares Short P.Month | 13,410 (K) |
| EPS | 1.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.98 |
| Profit Margin | 15.9 % |
| Operating Margin | 20 % |
| Return on Assets (ttm) | 7 % |
| Return on Equity (ttm) | 30.6 % |
| Qtrly Rev. Growth | 21.6 % |
| Gross Profit (p.s.) | 6.82 |
| Sales Per Share | 11.58 |
| EBITDA (p.s.) | 2.61 |
| Qtrly Earnings Growth | 109.9 % |
| Operating Cash Flow | 1,450 (M) |
| Levered Free Cash Flow | 783 (M) |
| PE Ratio | 38.63 |
| PEG Ratio | 0 |
| Price to Book value | 9.94 |
| Price to Sales | 6 |
| Price to Cash Flow | 18.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|